Sophiris Bio Inc. CEO Randy Woods said a cloud has lifted over its intratumoral injection agent topsalysin now that an investigation concluded that a patient fatality in a small Phase IIb study of localized prostate cancer was due to sudden cardiac death and unlikely to be related to the study drug.
Sophiris announced the outcome of the investigation, which included an autopsy, on Aug. 29, following the report of the death in June
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?